Early Benefit Assessments in Oncology in Germany: How Can a Clinically Relevant Endpoint Not Be Relevant to Patients?

After 4 years of early benefit assessment (EBA) in Germany, it is becoming evident that the Federal Joint Committee (FJC) frequently considers well-established clinical endpoints as not being relevant to patients. Focusing on assessments of oncology medicines, we analysed the FJC’s view on primary e...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruof, Jörg, Flückiger, Olivier, Andre, Niko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Current Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4561053/
https://www.ncbi.nlm.nih.gov/pubmed/26286202
http://dx.doi.org/10.1007/s40268-015-0100-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4561053/
https://www.ncbi.nlm.nih.gov/pubmed/26286202
http://dx.doi.org/10.1007/s40268-015-0100-1

Ejemplares similares